


**PRODUCT DATASHEET**
**ChemiScreen™ CCR5 Chemokine Membrane Preparation**


<b>CATALOG NUMBER:</b>	HTS010M	<b>QUANTITY:</b>	200 units
<b>LOT NUMBER:</b>	SC20180214	<b>VOLUME/CONCENTRATION:</b>	1 mL, 1 mg/mL

**BACKGROUND:** CCR5 is the receptor for CC chemokines MIP-1 $\alpha$ , MIP-1 $\beta$ , and RANTES (Raport *et al.*, 1996), and is preferentially expressed on Th1 lymphocytes (Loetscher *et al.*, 1998). CCR5 is a coreceptor for macrophage-tropic HIV, and its ligands potently inhibit HIV replication in human leukocytes (Cocchi *et al.*, 1995). In addition, HIV-infected patients with the nonfunctional CCR5 $\Delta$ 32 allele exhibit delayed onset of AIDS symptoms (Samson *et al.*, 1996), and pharmacological antagonism of CCR5 inhibits HIV-1 infection (Strizki *et al.*, 2001). Preclinical testing of small molecule antagonists of CCR5 has been hampered by low affinity of the compounds to rodent and dog CCR5, but two such compounds, maraviroc and AD101, have been shown to have potent antagonist activity at rhesus macaque CCR5, which differs from human CCR5 by 8 amino acids (Napier *et al.*, 2005; Billick *et al.*, 2004). One antagonist of human CCR5, SCH-C, does not block HIV entry through rhesus macaque CCR5, and one amino acid difference is responsible for the functional difference (Billick *et al.*, 2004). Rhesus macaque CCR5 membrane preparations are crude membrane preparations made from our proprietary stable recombinant cell lines to ensure high-level of GPCR surface expression; thus, they are ideal HTS tools for screening of agonists and antagonists of rCCR5.

**APPLICATIONS:** Radioligand binding assay



**Figure 1. Saturation binding for rhesus macaque CCR5.** 5 $\mu$ g/well CCR5 Membrane Preparation was incubated with increasing amount of <sup>125</sup>I-labeled MIP-1 $\alpha$  in the absence (total binding, TB) or presence (nonspecific binding, NSB) of 200-fold excess unlabeled MIP-1 $\alpha$ . Specific binding (SB) was determined by subtracting NSB from TB. Sample data from a representative lot.



**Figure 2. Competition binding for rhesus macaque CCR5.** CCR5 Membrane Preparation (5 μg/well) and wild-type Chem-1 Membrane Preparation (catalog # HTS000MC1) were incubated in a 96-well plate with 0.15 nM <sup>125</sup>I-labeled MIP-1α and increasing concentrations of unlabeled MIP-1α. More than 3-fold signal:background was obtained.

**SPECIFICATIONS:** 1 unit = 5 μg

$B_{max}$  for [<sup>125</sup>I]-MIP-1α binding: 1.3 pmol/mg protein

$K_d$  for [<sup>125</sup>I]-MIP-1α binding: ~0.46 nM

Signal:background: ≥3-fold

**TRANSFECTION:** Full-length rhesus macaque CCR5 cDNA encoding CCR5 (Accession Number: NM\_001042773.2).

**HOST CELLS:** Chem-1, an adherent cell line expressing the promiscuous G-protein, Gα15.

**RECOMMENDED ASSAY CONDITIONS:** Membranes are mixed with radioactive ligand and unlabeled competitor (see Figures 1 and 2 for concentrations tested) in binding buffer in a nonbinding 96-well plate, and incubated for 1-2 h. Prior to filtration, an FC 96-well harvest plate (EMD Millipore cat. # MAHF C1H) is coated with 0.33% polyethyleneimine for 30 min, then washed with Wash Buffer. Binding reaction is transferred to the filter plate, and washed 3 times (1 mL per well per wash) with Wash Buffer. The plate is dried and counted.

**Binding buffer:** 50 mM Hepes, pH 7.4, 5 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, 0.2% BSA, filtered and stored at 4°C

**Radioligand:** [<sup>125</sup>I]-MIP-1α (Perkin Elmer#: NEX-298 )

**Wash Buffer:** 50 mM Hepes, pH 7.4, 500mM NaCl , 0.1% BSA, filtered and stored at 4°C.

One package contains enough membranes for at least 200 assays (units), where a unit is the amount of membrane that will yield greater than 3-fold signal:background with <sup>125</sup>I labeled MIP-1α at 0.15 nM.

**PRESENTATION:**

Liquid in packaging buffer: 50 mM Tris pH 7.4, 10% glycerol and 1% BSA with no preservatives.

Packaging method: Membranes protein was adjusted to the indicated concentration in packaging buffer, rapidly frozen, and stored at -80°C.

**STORAGE/HANDLING:**

Store at -70°C. Product is stable for at least 6 months from the date of receipt when stored as directed. Do not freeze and thaw.

**REFERENCES:**

1. Abdi, R, *et al.* (2002) The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection. *Diabetes* 51: 2489-2495.
2. Belnoue, E, *et al.* (2003) CCR5 deficiency decreases susceptibility to experimental cerebral malaria. *Blood* 101: 4253-9.
3. Cocchi, F., *et al.* (1995) Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. *Science* 270: 1811-1815.
4. Loetscher, P, *et al.* (1998) CCR5 is characteristic of Th1 lymphocytes. *Nature* 391: 344-5.
5. Raport CJ, *et al.* (1996) Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. *J Biol Chem* 271: 17161-6.
6. Samson, M, *et al.* (1996) Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. *Nature* 382: 722-5.
7. Strizki, JM, *et al.* (2001) SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. *Proc. Natl. Acad. Sci. USA* 98: 12718-23.
8. Yang, YF, *et al.* (2002) A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. *Eur. J. Immunol.* 32: 2124-32.

**FOR RESEARCH USE ONLY; NOT FOR USE IN DIAGNOSTIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION**

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

No part of these works may be reproduced in any form without permission in writing.

**Eurofins Pharma Bioanalytics Services US Inc.** is an independent member of Eurofins Discovery Services